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Abstract: Response surface methodology (RSM) was used to optimize the process of preparing 
bovine serum albumin (BSA) nanoparticles by desolvation, then the resulting BSA nanoparticles 
(BSANPs) were conjugated with folate to produce a drug carrier system that can specifically 
target tumors. The anticancer drug, vinblastine sulfate (VBLS), was loaded to this tumor-specific 
drug carrier system for the purpose of overcoming the nonspecific targeting characteristics and 
side effects of the drug. A central composite design was applied for modeling the process, which 
was composed of four independent variables, namely BSA concentration, the rate of adding 
ethanol (ethanol rate), ethanol amount, and the degree of crosslinking. The mean particle size 
and residual amino groups of the BSANPs were chosen as response variables. The interactive 
effects of the four independent variables on the response variables were studied. The character-
istics of the nanoparticles; such as amount of folate conjugation, drug entrapment efficiency, 
drug-loading efficiency, surface morphology and release kinetics in vitro were investigated. 
Optimum conditions for preparing desired BSANPs, with a mean particle size of 156.6 nm 
and residual amino groups of 668.973 nM/mg, were obtained. The resulting folate-conjugated 
BSANPs (FA-BSANPs) showed a drug entrapment efficiency of 84.83% and drug-loading 
efficiency of 42.37%, respectively, and the amount of folate conjugation was 383.996 µM/g 
BSANPs. The results of this study indicate that using FA-BSANPs as a drug carrier system 
could be effective in targeting VBLS-sensitive tumors in the future.
Keywords: bovine serum albumin, vinblastine sulfate, folate, targeted drug delivery, nano-
particles, response surface methodology
Introduction
Even with the biological and pharmaceutical advancement that the scientific community 
has achieved, cancer is still, without doubt, one of the biggest killers worldwide. Vinca 
alkaloids, camptothecin, and paclitaxel are three kinds of the most commonly used plant 
derived chemotherapy agents.1 The four vinca alkaloids, namely vinblastine, vincristine, 
vindesine, and vinorelbine, are cell cycle specific mitotic inhibitors by binding to the 
microtubular proteins of the mitotic spindle, causing mitotic arrest and cell death. The 
four only differ in their antitumor spectra and toxicities.2 Vinblastine has poor aqueous 
solubility and serious side effects, however its transformation to a sulfate (vinblastine 
sulfate [VBLS]) has, to some extent, overcome its hydrophobicity. However, the 
systemic administration of VBLS is compromised by severe dose-limiting toxicity International Journal of Nanomedicine 2009:4 322
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leading to such side effects as leucopenia and anemia.3 This 
is not only due to the characteristics of VBLS itself, but more 
to the nonspecific targeting method of administrating the drug 
which damages both cancer cells and healthy noncancerous 
tissues that lead to the serious side effects when utilized in 
chemotherapy.
The current focus in the development of cancer therapies 
is on targeted drug delivery to provide therapeutic concentra-
tions of anticancer agents at the site of action and spares the 
normal tissues.4 To date most reports describe the delivery of 
VBLS are through passive targeting. Marinina and colleagues 
have encapsulated two vinca alkaloids, vincristine sulfate and 
VBLS, in poly(lactide-co-glycolide), to obtain microspheres 
that can release the drugs in a sustained manner.3 Zhigaltseva 
and their research group have compared the drug-loading and 
retention properties of vincristine, vinorelbine and vinblastine 
when entrapped in liposomes.5 Dandamudi has incorporated 
VBLS into liposomes in combination with magnetic drug 
targeting, which showed ideal drug-loading efficiency.6
In this study, we have tried to overcome the side effects 
of VBLS by using folate-conjugated-bovine serum albumin 
nanoparticles (FA-BSANP)s as a targeting drug carrier 
system. Folate has attracted significant attention as a targeting 
moiety due to its high binding affinity, small size, low cost and 
that a folate receptor is expressed, in high levels, on the surface 
of many human cancers although in very low levels on normal 
tissues.7,8 Folate has also been reported having a pronounced 
effect on improving cellular uptake and the efficacy of anti-
cancer drugs. Xue Han and colleagues have encapsulated 
9-nitro-camptothecin (9-NC) into folate-conjugated polymer 
micelles (FA-M-9-NC) by mixing folate-polyethyleneglycol-
distearoylphosphatidylethanolamine (folate-PEG-DSPE) 
and 1,2-Distearoyl-phosphatidyl ethanolamine-methyl-
polyethyleneglycol conjugate (MPEG-DSPE). In vitro drug 
efficacy against Hela cells showed increased cellular uptake 
for FA-M-9-NC than MPEG-DSPE-9-NC (M-9-NC) and free 
9-NC. The killing ability of FA-M-9-NC against Hela cells 
was also significantly improved when compared with M-9-NC 
and free 9-NC.9 Prabaharan and colleagues have entrapped 
doxorubicin into folate-conjugated amphiphilic hyper-
branched block copolymer (H40-PLA-b-MPEG/PEG-FA) 
micelleles. Due to the folate-receptor-mediated endocytosis, 
both cellular uptake and cytotoxicity of doxorubicin-loaded 
H40–PLA-b-MPEG/PEG–FA against 4T1 mouse mammary 
carcinoma cell line were higher than doxorubicin-loaded 
H40–PLA-b-MPEG micelles.10 Moreover, folate was also 
identified as an active targeting moiety of the blood–brain 
barrier, and has already been reported as being effective in 
targeting brain tumors.11 Bellamkonda and colleagues have 
formulated a phospholipid–polyethylene glycol (PEG) mask 
to protect folate from reticuloendothelial system (RES) clear-
ance, achieving a long-circulating targeting liposome for brain 
tumors. In vivo uptake studies, conducted with a 9L/lacZ 
glioma model, confirmed higher intracellular delivery of the 
obtained folate conjugated liposomes.12
The utilization of serum albumin as carriers for drug 
delivery is a part of ever growing pharmacological research. 
Lei Yang has entrapped 10-hydroxycamptothecin into bovine 
serum albumin nanoparticles (BSANP) to conquer its insolu-
bility in water, and obtained nanoparticles with the mean 
particle size of 600 nm using a high-speed emulsification 
method.13 Feng-Qian Li and colleagues have prepared sodium 
ferulate loaded BSANPs using a desolvation procedure which 
passively targeted liver cells through the effects of particle 
sizes and surface characteristics.14 Karmali has targeted clini-
cally approved paclitaxel-albumin nanoparticles to mice bear-
ing human cancer xenografts by conjugating them with two 
tumor-homing peptides, CREKA (Cys–Arg–Glu–Lys–Ala) 
and LyP-1(lysine permease), and the resulting targeted drug 
delivery systems were more effective than the unmodified 
ones.15 However, those studies only varied one factor at a 
time and as such their studies lack the representative effect 
of the interaction between different factors.16 Thus, we use 
a response surface methodology (RSM) for optimizing the 
process of producing BSANPs and studying the linear, square 
and interactive effects of various factors.
Therefore, we have focused on developing a FA-BSANPs 
targeting drug delivery system loaded with vinblastine sulfate 
(FA-BSANPs-VBLS), based on the optimized BSANPs 
preparation formulation that resulted from the RSM design. 
This system can passively target tumor cells passively 
through size effect and actively through folate, allowing a 
decreased drug dosage to reduce the undesirable side effects 
of VBLS. A freeze-drying process was adopted to obtain a 
dry powder form for long-term stability and preservation 
of the original pharmaceutical and biological properties 
the products.17 Since freeze-drying was one of the major 
techniques in producing the FA-BSANPs-VBLS, mannitol 
was added as a lyoprotectant, and its effect on preventing 
FA-BSANPs-VBLS from aggregation after freeze-drying was 
demonstrated by scanning electron microscopy (SEM).
Materials and methods
Materials
Folate (FA), bovine serum albumin (BSA) trypsin and 
2,4,6-trinitrobenzenesulfonic acid (TNBS) were all International Journal of Nanomedicine 2009:4 323
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obtained from Sigma Aldrich (St. Louis, MO, USA). The 
vinblastine sulfate was kindly provided by Hisun Pharma-
ceutical Co. Ltd (Zhejiang, China). N-hydroxysuccinimide, 
1,3-dicyclohexylcarbodiimide (DCC), ethanol and the other 
reagents were all analytical grade.
Preparation and optimization  
of BsANPs by RsM
The BSANPs were prepared as previously described using a 
desolvation technique.18 As shown in Figure 1a, briefly, after 
BSA (3.21 mg) was first dissolved in deionized water (1 mL), 
a desolvating reagent, ethanol (4.23 mL), was added with a 
peristaltic pump TI/62/20 (Medorex, Norten-Hardenberg, 
Germany) (2.96 mL/min) at room temperature. Hereafter, 
glutaraldehyde solution (11.5µL, 0.25%) was added to 
crosslink amino groups of the BSANPs. The crosslinking 
process was performed through stirring the suspension over 
a time period of 24 hours.
The desolvating reagent was removed by evaporation 
using a rotary evaporator R201BL (SENCO, Shanghai, 
China) at 40 °C, and then the BSANPs were redispersed to 
the original volume with deionized water. The redispersion 
process was performed in an ultrasonication bath TI-H-5 
(Elma, Singen, Germany) over 10 minutes.
The above BSANPs preparation procedure was opti-
mized by a four-factor, three-level central composite design 
(CCD), with BSA concentration (X1), ethanol rate (X2), 
ethanol amount (X3) and theoretical crosslinking degree (X4) 
as the independent variables (Table 1). The levels of those 
independent variables were based on preliminary trials. 
Peristaltic pump
Peristaltic pump
Ethanol
VBLS solution 0.25% glutaraldehyde solution
Centrifugation and
freeze-drying
NHS-folate
(in DMSO)
Rotary evaporator
and reconstitution
in deionized water
Dialysis against
deionized water
BSANP
BSA solution
FA-BSANP
FA-BSANP solution
FA-BSANPs-VBLS
FA-BSANPs-VBLS
FA-BSANP
Peristaltic pump Peristaltic pump
FA-BSANP
Water (pH=10)
BSANP
NHS-folate
A B
Figure 1 schematic description of the preparation procedure of FA-BsANPs-VBLs A) BsANPs were produced with a desolvation technique, and then Nhs-folate was 
conjugated under alkaline condition, ph = 10 B) FA-BsANP powder was reconstituted in deionized water, followed by the addition of VBLs solution with peristaltic pump. 
VBLs was loaded by means of electrostatic interaction.
Abbreviations: BsANP, bovine serum albumin nanoparticles; FA-BsANP, folate-conjugated-bovine serum albumin nanoparticles; FA-BsANPs-VBLs, folate-conjugated-bovine 
serum albumin nanoparticles-vinblastine sulfate; Nhs-folate, N-hydroxysuccinimide ester of folate; VBLs, vinblastine sulfate.International Journal of Nanomedicine 2009:4 324
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The mean particle size and residual amino groups of the 
resulting BSANPs were used as response variables. Design-
Expert® Version 7.0.0 software (State-Ease Inc., Minneapolis, 
MN, USA) was applied to generating and evaluating the 
statistical experimental design.
Preparation of vinblastine sulfate-loaded 
folate-conjugated albumin nanoparticles
Preparation of FA-BsANPs
The method used for preparing the N-Hydroxysuccinimide 
ester of folate (NHS-folate) was reported by Lee and 
Low.19
The carboxylic groups of the NHS-folate were conju-
gated with the amino groups of the BSANPs under alkaline 
condition (pH 10.0). NHS-folate (3 mg) was dissolved 
in dimethyl sulfoxide (1.0 mL) and added to a BSANPs 
suspension stirring continously (Figure 1a). The pH value 
of the BSA suspension was adjusted using 1M carbonate/
bicarbonate buffer. This reaction took 45 min. Then the 
unassociated NHS-folate in the mixture was removed by 
dialyzing it against deionized water using Slide-A-Lyzer® 
dialysis cassettes with a molecular weight cut-off of 3500Da 
for 48 hours (Pierce Biotechnology, Rockford, IL, USA), 
followed by freeze-drying. The FA-BSANPs obtained 
after freeze-drying were a yellow powder.
Preparation of vinblastine  
sulfate-loaded FA-BsANPs
In the preliminary trials, we found that the produced drug 
carrier system would be unstable if VBLS was entrapped dur-
ing the step when the BSANPs were formed. Thus a two-step 
preparation procedure was adopted, where the FA-BSANPs 
were used as porous drug carriers to some extent.20 The VBLS 
was loaded mainly through electrostatic interaction between 
positive charges of the drug and negative charges of the 
FA-BSANPs, when the pH value of the solution was higher 
than the isoelectric point of BSA. This mechanism of loading 
drugs has also been reported by Huang and colleagues.21 
As illustrated in Figure 1b, the FA-BSANPs powder was 
reconstituted in deionized water, and then the VBLS solu-
tion was added into the resulting suspension. This mixture 
was stirred for 24 hours, allowing the VBLS to diffuse into 
the inner matrix of the FA-BSANPs. Thereafter, the mixture 
was freeze-dried followed by reconstitution in deionized 
water. In order to keep the VBLS in the FA-BSANPs matrix, 
glutaraldehyde solution (150 µL, 0.25%) was added to the 
reconstitution solution to further crosslink the residual amino 
groups of the FA-BSANPs.
This reconstitution solution was centrifuged (20,000 × g, 
10 min) for the purpose of separating the unloaded VBLS. 
This purification process was repeated three times. After each 
centrifugation, the residue was redispersed, to the original 
volume, with deionized water, using a mechanical stirrer. The 
supernatant from each centrifugation was collected together 
to determine the drug entrapment efficiency and drug-loading 
efficiency. The resulting solution was freeze-dried again 
after final redispersion. The lyoprotectant, mannitol, would 
be added to the final redispersed solution (5% of total mass) 
before freeze-drying if needed.
characterization of the FA-BsANPs-VBLs
Quantification of the residual amino groups  
on the BsANPs
The residual amino acid groups on the BSANPs were 
determined using trinitrobenzesulphonic acid (TNBS) assay 
according to literature with minimum change.22
The BSANPs were washed three times with water 
by centrifugation at 20,000 × g for 20 min, followed by 
redispersion with 4% sodium bicarbonate solution (pH 8.5). 
Two milliliters of the BSANPs dispersion and 4.0 mL of 
TNBS solution (4.0 mol/mL in 4% sodium bicarbonate 
solution) were added. The reaction mixture was shaken at 
400 rpm for one hour at 40 °C. The samples were again 
centrifuged (20,000 × g; one hour) to separate the BSANPs 
from the supernatant. In order to measure any unreacted 
TNBS, 0.9 mL of the supernatant was added to 0.1 mL of 
an aqueous valine solution (40 mol/mL) and incubated at 
40 °C in the dark for one hour. Following this 5 mL of HCl 
(0.5 mM/L) were added and the absorbance of solution was 
measured at 410 nm against a blank prepared, as described 
above, but containing 0.1 mL of trichloroacetic acid (1%) 
instead of the valine solution. The residual amino groups on 
the particle surface were calculated relative to a TNBS refer-
ence that was treated in the same manner as described above, 
using water instead of the BSANPs dispersion.
Table 1 Factors and their levels in RsM designs
Independent variables Symbol Coded levels
-1 0 1
BsA con.(mg/ml) X1 2 3 4
ethanol rate (ml/min) X2 1.625 2.75 3.875
ethanol amount (ml) X3 2.375 4.25 6.125
Degree of crosslinking (%) X4 20 30 40
Abbreviations: BsA, bovine serum albumin; RsM, response surface methodology.International Journal of Nanomedicine 2009:4 325
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Determination of folate content 
associated with the BsANPs
The amount of NHS-folate that had been conjugated with 
BSANPs was evaluated using the method described by 
Zhang and colleagues.23 Briefly, after dialysis against 
deionized water, the FA-BSANPs (1 mg in 10 mL deionized 
water) were digested by trypsin (50 µg/mg BSA). Then 
the resultant tryptic hydrolysis of the FA-BSANPs was 
scanned using a UV-spectrophotometer (268 nm to 
450 nm) (SHIMADZU, Tokyo, Japan), using BSANPs 
and tryptic hydrolysis of BSANPs as controls. The extent 
of NHS-folate conjugated was determined relative to a 
NHS-folate reference: y = 14.951x - 0.847, R2 = 0.999 
(y: NHS-folate concentration, µg/mL; x: absorption). The 
content of the conjugated folate was the mean of triplicate 
experiments.
Mean particle size and surface 
morphology of nanoparticles
The mean particle size of obtained nanoparticles was deter-
mined by dynamic light scattering using Zetasizer (Malvern 
Instrument, Worcestershire, England) with angle detection 
at 90°. Each experimental preparation was conducted in 
triplicate, and the mean particle size was calculated.
The morphology of the samples was investigated 
using scanning electron microscopy (FEI Co., Eindhoven, 
Netherland).
Drug encapsulation efficiency  
and loading efficiency
The VBLS in the supernatant was examined by high 
performance liquid chromatography (HPLC). A Waters high 
performance liquid chromatograph (Waters Corporation, 
Milford, MA, USA), consisting of a Waters 600 Controller 
equipped with a Waters 717 plus autosampler, and a Waters 
2487 UV detector. The samples were chromatographed at 
25 °C by injecting of 10 µL of sample into a Diamonsil C18 
column, (250 mm × 4.6 mm, 5 µm; Dikma Technologies, 
Beijing, China). The mobile phase was composed of an 
aqueous solution of ammonium carbonate (0.5%) and 
methanol 70:30 (v/v). The wavelength was set to 215 nm. 
The drug entrapment efficiency (DEE) and drug-loading 
efficiency (DLE) were calculated using equations as 
previously reported by Park and colleagues.7
1DEE =
VBLS (total) VBLS(in supernatant)
VBLS (total)
-
×100%
 
(1)
2DLE
VBLS (total) VBLS (in supernatant)
FA BSANPs VBLS
=
-
- -
×100%
 
(2)
Drug release study
VBLS release from FA-BSANPs was determined in 
phosphate buffered saline (0.15 M, pH 7.4) at 37 °C. FA-
BSANPs-VBLS suspension (5.8 mg/mL, 10 mL; without 
mannitol) was placed in Slide-A-Lyzer® dialysis cassettes 
(MWCO 3500), and then the dialysis cassettes was immersed 
in a 400 mL beaker containing 200 mL release buffer. The 
beaker was then placed in an incubator shaker at 37 °C and 
100 rpm. The release buffer (3 mL) was withdrawn from 
the beaker and replaced with 3 mL fresh release buffer at 
predetermined time intervals. The VBLS concentration in 
each collected release buffer sample was determined by 
HPLC using conditions as described above. The accumula-
tive release percentage was calculated using the following 
equations:
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where Ci represents the VBLS concentration of each sample 
withdrawn at predetermined time intervals, Ci′ represents 
the increase of the VBLS concentration during each time 
interval, V represents the volume of the release buffer, 
V0 represents the volume of each withdrawn sample, M is 
the VBLS loaded in the FA-BSANPs-VBLS, and Qi is 
the accumulative release percentage at predetermined time 
point.
The drug release studies were carried out in triplicate 
for each of the samples.
Results and discussion
Model analysis
Particle size plays a key role in determining body distribu-
tion of the nanoparticles after being injected in vivo and in 
facilitating their access into cancer cells after the folate has 
targeted cancer tissues. In order to investigate the mechanism 
determining the mean particle size of the BSANPs, we 
studied the linear, square, and interactive effects of the 
independent variables on particle size using RSM. On 
the other hand, the degree of crosslinking could influence the 
matrix structure of the BSANPs and therefore influence its drug International Journal of Nanomedicine 2009:4 326
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carrying capacity – since VBLS diffuses into the BSANPs 
mainly through channels within the matrix of the BSANPs. 
The degree of crosslinking can be controlled by adjusting 
the amount of glutaraldehyde. However, the association 
of folate with BSANPs is through conjugating the amino 
groups of BSA molecules with the carboxylic groups of the 
folate. Thus, the largest amount of the glutaraldehyde we 
added can only theoretically crosslink 50% of the overall 
amino groups of BSA molecules, leaving room for the folate 
conjugation.24 This model was used to minimize the particle 
size while maximize the amino groups left on the surface of 
the BSANPs.
For the response surface methodology involving CCD, 
a total of 30 experiments were conducted for four factors 
at three levels. The uncoded independent variables and 
the observed responses for the 30 experiments are shown 
in Table 2. A suitable polynomial equation involving 
the main individual effects and interaction factors was 
selected based on the estimation of several statistical 
parameters, such as the multiple correlation coefficient 
(R2), adjusted multiple correlation coefficient (adjusted 
R2) and the predicted residual sum of squares (PRESS), 
provided by the Design-Expert® software. The smaller 
the PRESS statistic is, the better the model fits to the 
data point.25 As shown in Table 3, due to their smallest 
value of PRESS, two quadratic models were chosen as a 
suitable statistical model for the optimization of the mean 
particle size and residual amino groups, respectively. 
The lack of fit of both models was statistically insig-
nificant, as shown in Table 3. The models of each of the 
response variables generated by the design are given in 
the following equations.
Mean particle size = 122.88 + 26.25X1 + 13.06X2 + 0.33X3
  - 5.30X4 + 11.81X1X2 - 1.17X1X3 
  - 4.21X1X4 + 1.83X2X3 - 3.08X2X4
  + 2.37X3X4 + 30.11X1
2 + 9.84X2
2 
  + 5.92X3
2 + 10.41X4
2  (5)
Residual amino groups = 671.94 - 10.71X1 + 2.95X2 
  - 0.011X3 - 20.52X4 - 5.09X1X2 
  + 0.22X1X3 + 9.70X1X4 + 0.15X2X3 
  - 4.73X2X4 - 0.1X3X4 - 110.03X1
2 
  - 105.19X2
2 - 104.78X3
2 - 6.51X4
2 
  (6)
Analysis of variance (ANOVA) was applied to determine 
the significance and the magnitude of the effects of the main 
variables and their interactions on the response variables 
(Table 4). The regression models obtained were used to 
generate the three-dimensional response surface plots for the 
independent variables. According to the ANOVA, the BSA 
concentration and the rate of adding ethanol have significant 
effects on the particle size. Therefore, these variables were 
chosen to plot the response surface for the particle size while 
holding amount of ethanol and crosslinking degree at central 
points, 4.25 mL and 30%, respectively. As can be seen from 
Figure 2, the particle size increases markedly as the BSA con-
centration increases. The particle size had a slight decrease 
as the rate of adding ethanol is increased up to 2.75 mL/min, 
over this rate, the particle size had a minor increase when 
the rate of adding ethanol was increased. There is a more 
Table 2 experimental design and results of the central composite 
design
Assay Variables Responses
  X1 X2 X3 X4 Y1 (nm) Y2 (nmol/mg)
1 4 1.625 6.125 20 187.6 345.813
2 4 3.875 2.375 20 264.6 342.91
3 4 3.875 2.375 40 215.1 323.377
4 4 1.625 2.375 40 174.9 324.485
5 5 2.75 4.25 30 282.2 210.546
6 4 1.625 2.375 20 193.2 346.226
7 3 2.75 0.5 30 136.7 253.779
8 2 3.875 6.125 20 178.2 404.353
9 3 2.75 4.25 30 125.9 678.07
10 2 3.875 2.375 20 167.9 405.421
11 3 2.75 4.25 30 93.0 674.001
12 2 3.875 6.125 40 166.5 325.355
13 3 2.75 4.25 30 113.8 671.627
14 2 3.875 2.375 40 158.0 325.593
15 3 2.75 4.25 30 139.4 670.796
16 4 1.625 6.125 40 175.3 324.168
17 2 1.625 6.125 20 158.2 366.464
18 4 3.875 6.125 40 238.2 323.332
19 1 2.75 4.25 30 173.0 254.491
20 3 2.75 4.25 30 138.2 670.558
21 4 3.875 6.125 20 253.0 345.83
22 3 0.5 4.25 30 140.9 251.939
23 3 2.75 4.25 10 150.0 688.202
24 2 1.625 2.375 20 154.6 366.701
25 2 1.625 6.125 40 154.7 325.751
26 2 1.625 2.375 40 152.1 325.553
27 3 5 4.25 30 152.2 251.82
28 3 2.75 4.25 30 127.0 666.558
29 3 2.75 8 30 125.0 253.245
30 3 2.75 4.25 50 147.6 604.978
Abbreviations: BsA concentration (X1), ethanol rate (X2), ethanol amount (X3) and 
theoretical crosslinking degree (X4).
Particle size Y1, residual amino groups, Y2.International Journal of Nanomedicine 2009:4 327
Vinblastine sulfate-loaded bovine serum albumin nanoparticles Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
pronounced effect with alterations in the BSA concentration, 
which can be foreseen from the ANVOA, since the P value 
of the BSA concentration is less than 0.0001.
According to the ANVOA, the BSA concentration 
and degree of crosslinking had pronounced effects on the 
residual amino groups. As shown in Figure 3a, when the 
amount of ethanol and crosslinking degree were held at 
center point, namely 4.25 mL and 30%, the residual amino 
groups have a maximal value as the BSA concentration and 
ethanol rate arrive at 3 mg/mL and 2.75 mL/min, respec-
tively. Figure 3b indicate that the residual amino groups 
decreases as the crosslinking degree increases. Due to the 
interaction between the degree of crosslinking and the BSA 
concentration, the residual amino groups achieved a peak 
value of 661.386 nM/mg when the BSA concentration and 
degree of crosslinking were approximately 3 mg/mL and 
35%, respectively. As to the interaction between the rate 
of ethanol added and degree of crosslinking (Figure 3c), 
the same pattern was observed. In this case, the optimal 
value of the residual amino groups was 661.38 nM/mg. 
Theoretically, the degree of crosslinking should be the only 
parameter that has significant effect on the residual amino 
groups.24 However, the observed results may be due to the 
fact that the residual amino groups on the BSANPs are also 
influenced by the particle size, since the smaller the particle 
is, the larger the relative surface area, thus there are more 
amino groups exposed on the surface of the nanoparticles. 
In another word, the two variables that had significant effects 
Table 3 ANOVA for the models predicted for each response
Source Y1 Y2
  SS DF MS F-value P-value SS DF MS F-value P-value
Model 50701.321 14 3621.523 8.522 0.0001 768343.274 14 54881.662 1430.314 0.0001
X1 16542.75 1 16542.75 38.926 0.0001 2750.79 1 2750.79 71.69 0.0001
X2 4095.094 1 4095.094 9.636 0.007 208.7 1 208.67 5.439 0.034
X3 2.60 1 2.60 0.006 0.939 0.003 1 0.00299 0.0000778 0.993
X4 675.220 1 675.220 1.589 0.227 10108.715 1 10108.715 263.451 0.0001
X1X2 2230.201 1 2230.201 5.248 0.037 415.121 1 415.121 10.819 0.005
X1X3 21.856 1 21.856 0.051 0.824 0.762 1 0.762 0.0199 0.89
X1X4 283.081 1 283.081 0.666 0.428 1506.761 1 1506.761 39.269 0.0001
X2X3 53.656 1 53.656 0.126 0.727 0.342 1 0.342 0.0089 0.926
X2X4 151.906 1 151.906 0.357 0.559 357.317 1 357.317 9.312 0.0081
X3X4 89.776 1 89.776 0.211 0.652 0.161 1 0.161 0.0042 0.949
X1
2 24859.161 1 24859.161 58.495 0.0001 332053.086 1 332053.086 8653.895 0.0001
X2
2 2657.250 1 2657.250 6.253 0.025 303480.724 1 303480.724 7909.248 0.0001
X3
2 960.529 1 960.529 2.26 0.154 301130.481 1 301130.481 7847.997 0.0001
X4
2 2969.646 1 2969.646 6.988 0.018 1162.392 1 1162.392 30.294 0.0001
Residual 6374.679 15 424.979 575.555 15 38.37
LOFa 4865.711 10 486.571 1.612 0.312 501.456 10 50.146 3.384 0.095
Pure error 1508.968 5 301.794 74.099 5 14.82
cor Total 57076 29       768918.83 29      
aLOF = lack of fit.
Abbreviations: BsA concentration (X1), ethanol rate (X2), ethanol amount (X3) and theoretical crosslinking degree (X4).
Particle size Y1, residual amino groups, Y2.
Table 4 Optimization formulation of the BsANPs and the predicted and observed responses
Factors Predicted responses Observed responses Predicted errorc
X1 X2 X3 X4 Y1 Y2 Y1 ± sDb Y2 ± sDb Y1 Y2
3.21 2.96 4.23 20 150 nm 674.598 nmol/mg 156.6 ± 3.8 668.973 ± 27.5 -4.427% 0.834%
bn = 5.
cPredicted error (%) = (predicted value - observed value)/predicted value × 100%.
Abbreviation: BsANP, bovine serum albumin nanoparticles.International Journal of Nanomedicine 2009:4 328
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on particle size interacted with the fourth variables, the degree 
of crosslinking, resulting in the data obtained.
Nanoparticles with the mean particle size of 100 to 
200 nm have an enhanced permeability and retention 
(EPR) effect, which allowed the preferred accumulation 
of drug-loaded nanoparticles within tumors.26 Moreover, 
pegylated liposomes with the mean particle size of 120 to 
160 nm were found to circulate in blood for long periods 
of time.27 Hence, 150 nm was chosen as the target for the 
optimization of the mean particle size of the BSANPs, while 
maximization was the chose aim of the optimization for the 
residual amino groups. The optimum values of the variables 
were obtained by graphical and numerical analyses using 
the Design-Expert® software and based on the criterion of 
desirability.25 The optimized formulation was achieved with 
3.21 mg/mL BSA, 2.96 mL/min of ethanol rate, 4.23 mL 
ethanol, and 20% crosslinking degree. The desirability of this 
formulation is 0.986. Thus, five new batches of the BSANPs 
were prepared to confirm the validity of the optimization 
procedure. Table 4 indicates a predicted error of -4.427% 
for mean particle size and a predicted error of 0.834% for 
residual amino groups, respectively. Thereafter, all of the 
following experiments were conducted using BSANPs 
produced by this optimized formulation.
characterization of the nanoparticles
Determination of the conjugation of folate to BsANPs
NHS-folate had an absorption maximum at 281 nm, 
the absorption peak of digested FA-BSANPs at 281 nm 
confirmed the successful conjugation of folate with BSANPs 
(Figure 4). Moreover, according to the calibration curve of 
NHS-folate, 383.996 µM NHS-folate was conjugated with 
1 g of BSANPs, which was rather high compared with tradi-
tional procedures of preparing the BSANPs.22 On one hand, 
this phenomenon indicates that the amino groups of the BSA 
molecules were consumed when superfluous glutaraldehyde 
was added to crosslink BSANPs in the traditional procedures. 
On the other hand, it verifies our postulation that the residual 
amino groups can be adjusted when the crosslinking agent 
was added stoichiometrically.
Drug entrapment and loading efficiency
We investigated the influence of different particle size of the 
FA-BSANPs and varying the initial weight ratio of the VBLS 
to the FA-BSANPs on the drug entrapment efficiency and the 
drug-loading efficiency. The NO.11, NO.23 and the optimized 
formulation designed by response surface methodology were 
used in this part, considering the mean particle size of the result-
ing BSANPs (93, 156.6, and 282.2 nm). As can be seen from 
Figure 5, the larger the nanoparticles are, the higher the drug 
entrapment efficiency, as well as the drug-loading efficiency. 
This may result from the fact that larger FA-BSANPs have 
a larger volume, thus can hold more drugs. The highest 
drug entrapment efficiency and drug-loading efficiency 
were obtained, (namely 94.78% and 47.66%), when the 
FA-BSANPSs had an average diameter of 282.2 nm. On the 
other hand, in each group with different diameters, the drug 
entrapment efficiency and the drug-loading efficiency 
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Figure 4 Determination of Nhs-folate conjugation with BsANPs. A) Nhs-folate has two absorption peaks, namely 281 nm and 345 nm. B) Tryptic hydrolysis FA-BsANPs has 
absorption at 281 nm, and the unassociated Nhs-folate has been removed by dialysis. C) and D) BsANPs and tryptic hydrolysis have no affect on Nhs-folate absorption.
Abbreviations: BsANP, bovine serum albumin nanoparticles; FA-BsANP, folate-conjugated-bovine serum albumin nanoparticles; Nhs-folate, N-hydroxysuccinimide ester 
of folate.
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sulfate;    VBLs, vinblastine sulfate.
increased as the initial weight ratio of VBLS to BSA increased 
from 1:6 to 1:2, which indicates there are maximal carrying 
capacities for the FA-BSANPs.
Despite the high drug entrapment efficiency and 
drug-loading efficiency of NO.5, the mean particle size 
and the resulting characteristics are still the priority of 
preparing the tumor-specific drug carrier. Moreover, the drug 
entrapment efficiency and the drug-loading efficiency of the 
optimized formulation were acceptable for drug delivery 
system.28 Thus, the FA-BSANPs-VBLS prepared with the 
optimized formulation were used in the drug release study 
in vitro.International Journal of Nanomedicine 2009:4 331
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surface characteristics of BsANPs
In order to examine and compare the surface characteristics 
of the nanoparticles resulting from each step in prepar-
ing the optimal formulation of FA-BSANPs-VBLS, they 
were prepared and scanned using SEM. As shown in 
Figure 6, all of the nanoparticles were globular-shaped. 
The blank BSANPs were evenly distributed in particle 
size and had a tight structure, while the conjugation of the 
folate with the BSANPs changed the surface characteris-
tics of BSANPs, and led to agglomeration to some extent 
(Figure 6b). The adjustment of pH value to alkaline condi-
tions (pH = 10) before conjugating the folate may account 
for this phenomenon, since the pH value also plays a sig-
nificant role in stabilizing the nanoparticles.29 However, 
the addition of mannitol in the final products can solve this 
problem, as can be seen in Figure 6d, since the aggrega-
tion still existed after VBLS was loaded into FA-BSANPs 
(Figure 6c). The FA-BSANPs-VBLS were well dispersed after 
adding mannitol. Moreover, no crystal precipitations were 
A B
C D
Figure 6 comparison of seM images of nanoparticles obtained in the steps of producing the optimal formulation of folate-conjugated-bovine serum albumin nanoparticles-
vinblastine sulfate (FA-BsANPs-VBLs):  A) bovine serum albumin nanoparticles (BsANPs); B) folate-conjugated-bovine serum albumin nanoparticles (FA-BsANPs); C) FA-BsANPs-
VBLs; D) FA-BsANPs-VBLs with mannitol.
Abbreviations: BsANP, bovine serum albumin nanoparticles; FA-BsANP, folate-conjugated-bovine serum albumin nanoparticles; FA-BsANPs-VBLs, folate-conjugated-bovine 
serum albumin nanoparticles- vinblastine sulfate; Nhs-folate, N-hydroxysuccinimide ester of folate;   VBLs, vinblastine sulfate; seM, scanning electron microscopy.
Figure 7 Appearance of FA-BsANPs-VBLs solution, 48 hours after reconstitution.
Abbreviation:  FA-BsANPs-VBLs, folate-conjugated-bovine serum albumin 
nanoparticles-vinblastine sulfate.International Journal of Nanomedicine 2009:4 332
Zu et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
observed in FA-BSANPs-VBLS, and FA-BSANPs-VBLS 
with mannitol, which demonstrates the stability and 
applicability of the obtained drug delivery system.
Drug release property  
of the drug carrier system
The FA-BSANPs-VBLS powder without mannitol was 
reconstituted to carry out in vitro drug release experiments. 
The appearance of the reconstitution solution was translucent, 
tainted with light yellow color after being reconstituted for 
48 hours (Figure 7).
The batch used to conduct the drug release experiment 
had an average drug entrapment efficiency of 88.06% and 
an average drug-loading efficiency of 39.14%, respectively 
(in triplicate). The drug carrier system had a burst release 
in 12 hours and a slow release up to 56 hours, releasing 
approximately 30% and 80% of VBLS respectively (Figure 8). 
The observed release curve indicates that the drug carrier 
system had a sustained release property. Moreover, the 
observed release curve was analysed using the Originpro 
(Version 7.5) software (OriginLab Corporation, Northampton, 
USA). The observed release model was in close agreement 
with the first order kinetics model, as shown in Figure 8, with 
R2 of 0.991 and equation of y = –106.451 e(-x/35.151) + 103.386. 
The fitting of the first order kinetics model confirmed the 
sustained release feature of this drug delivery system.
Conclusions
The RSM has been successfully applied to optimize the 
procedure for the preparation of BSANPs. Our results indi-
cated that the BSA concentration and the ethanol addition 
rate played significant roles in determining the BSANPs 
particle size, and it is mainly through these interactive 
effects that the four independent variables affected the 
amount of residual amino groups on the surface of the 
BSANPs. The VBLS entrapment and loading efficiency 
were investigated, and extra considerations were paid to 
the influence of the particle sizes on the drug entrapment 
efficiency and drug-loading efficiency. Both drug entrap-
ment efficiency and drug-loading efficiency were improved 
with increased particle size, as well as an increased VBLS 
to BSA ratio. The surface characterization demonstrated that 
the FA-BSANPs-VBLS with mannitol was a suitable drug 
delivery system, and the in vitro release study verified its 
sustained release characteristics. Furthermore, the in vivo 
properties of the FA-BSANPs-VBLS targeting drug delivery 
system will be investigated in the future.
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